Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
Items 401–500 of 808
Supreeyasakon, S., Traipattanakul, J., Hemapanpairoa, J., Juntanawiwat, P., & Santimaleeworagun, W. (2024) · PLoS ONE · doi:10.1371/journal.pone.0313944 · Cited by 4
Urinary Tract Infection Treatment
Yassin, A., Kaye, K. S., & Bhowmick, T. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.03.007 · Cited by 3
Saavedra‐Lozano, J., Slöcker-Barrio, M., Fresán‐Ruiz, E., Grasa, C. D., Pedraz, L. M., Menasalvas, A. I., & Sebastián, M. D. M. S. (2024) · Anales de Pediatría · doi:10.1016/j.anpedi.2024.04.011 · Cited by 3
Saavedra‐Lozano, J., Slöcker-Barrio, M., Fresán‐Ruiz, E., Grasa, C. D., Pedraz, L. M., Menasalvas, A. I., & Sebastián, M. D. M. S. (2024) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2024.05.012 · Cited by 5
Almangour, T. A., Aldajani, G. A., Alhijji, A., & Alsharidi, A. (2024) · IDCases · doi:10.1016/j.idcr.2024.e02020 · Cited by 3
Staten, A. R., & Baker, D. E. (2024) · Hospital Pharmacy · doi:10.1177/00185787241269112 · Cited by 3
Zhang, Y., Zou, C., Qin, J., Li, M., Wang, X., Wei, T., & Wang, H. (2024) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2024/5459549 · Cited by 3
“And carbapenem antibiotics was not be hydrolyzed by ESBL, so that it was served as the primary therapeutic approach for treating infections induced by ESBL-producing bacteria [11].”
Backgroundde la Torre, J. C. G., Frenkel, A., Chavez-Lencinas, C., Rendon, A., Fabian, M., Cáceres-DelAguila, J. A., & Hueda-Zavaleta, M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0331266 · Cited by 3
Akçam, F. Z., Pekbay, B., Ünal, O., Ertugrul, T., KOÇLUK, F., Uygun, A., & Turker, A. H. (2025) · Cureus · doi:10.7759/cureus.90711 · Cited by 3
“However, the prevailing guidelines do not advocate combination therapy due to the absence of compelling evidence substantiating its efficacy in cases where susceptibility to a preferred antibiotic is demonstrated [8].”
The iron-infection axis revisited: From mechanistic insights to therapeutic frontiers
Moro, H. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102818 · Cited by 4
Medrzycki, M., Stanton, R. A., Rankin, D. A., Horwich-Scholefield, S., Mahmud, A., Maruca, T., Brister, S., Hsiao, L., Vaeth, E., Therrien, M., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2025.101201 · Cited by 3
“28 However, durlobactam does not inhibit metallo-β -lactamases such as NDM, and NDM-CRAB from an international collection of isolates showed high minimum inhibitory concentrations to sulbactam–durlobactam in-vitro testing.”
Zhao, B. T., Wang, Q., Lu, J., Fu, Y., Cui, D., He, J., Zhai, Z., Ma, Y., & Li, G. (2025) · Journal of Hospital Infection · doi:10.1016/j.jhin.2025.10.020 · Cited by 3
Ji, B., Li, Y., Yan, X., Sun, Q., Zhang, G., Chai, W., Xu, P., Ma, J., Hu, Y., Xie, J., et al. (2025) · Trials · doi:10.1186/s13063-025-09319-2 · Cited by 3
“Biofilm-associated pathogens need antibiotic levels 100–1000 times the MIC, which are difficult to achieve intravenously, potentially reducing efficacy and promoting antibiotic resistance [13, 14].”
Wu, M., Li, J., Zhou, Z., Chen, Y., Qiu, M., Dou, L., Xu, L., Wu, X., & Ren, J. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf504 · Cited by 3
Castellano-Sánchez, L., Aguilera-Franco, M., Albendin-Moreno, M., Olvera-Porcel, M. D. C., Rosales‐Castillo, A., Navarro‐Marí, J. M., & Fernández, J. G. (2026) · Apmis · doi:10.1111/apm.70146 · Cited by 3
“Our data support the IDSA [5] and ESCMID [29] recommendations, which limit the use of cefepime and PIP/TAZ for ESBL infections outside the urinary tract, even when they show in vitro susceptibility.”
InfluentialJousset, A. B., Girlich, D., Oueslati, S., Birer, A., Delaval, A., Guyot, C., Rezzoug, I., Emeraud, C., Naas, T., Bonnin, R. A., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01335-25 · Cited by 3
Label-Free Differentiation of Antimicrobial Resistance Groups Using Raman Spectroscopy
Pistiki, A. C., Ryabchykov, O., Wagenhaus, A., Bocklitz, T. W., Deinhardt-Emmer, S., Löffler, B., Rösch, P., & Popp, J. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c03370 · Cited by 4
Minor non-fermenting Gram-negative bacilli in Europe, 2020–2024 (MINOFEu)
Bianco, G., Bastos, P. A. D., Gartzonika, K., Christaki, E., Mavromanolaki, V. E., Maraki, S., Spiliopoulou, A., Giormezis, N., Lengerova, G., Kalchev, Y., et al. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107772 · Cited by 3
Boattini, M., Bastos, P. A. D., Gartzonika, K., Christaki, E., Mavromanolaki, V. E., Maraki, S., Spiliopoulou, A., Giormezis, N., Lengerova, G., Kalchev, Y., et al. (2026) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2026.117384 · Cited by 3
Yu, J., Gao, W., & Chen, Y. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1795720 · Cited by 3
Jung, E., Park, J. J., Oh, H. S., & Jung, Y. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag444 · Cited by 3
Arıcı, N., Tanrıverdi, E. S., Çalık, Ş., Kansak, N., Adaleti, R., Otlu, B., & Aksaray, S. (2023) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2023.100431 · Cited by 3
Maranchick, N. F., Webber, J., Al‐Shaer, M. H., Felton, T., & Peloquin, C. A. (2023) · Antibiotics · doi:10.3390/antibiotics12121696 · Cited by 3
“Multidrug-resistant (MDR) isolates were defined as extended spectrum beta-lactamase (ESBL) Enterobacterales , carbapenem-resistant (CR) Enterobacterales , MDR-Pseudomonas aeruginosa , MDR-Acinetobacter baumannii , or any bacteria non-susceptible to ≥ 1 agent in ≥ 3 antimicrobial categories [4,28–30].”
BackgroundPitart, C., Santillana, G. E., Narváez, S., Sellarés, A., Campo, I., Casals‐Pascual, C., & Soriano, À. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04749-3 · Cited by 3
Aon, M. H., Aoun, A. H., Shami, A. A., Alharbi, A., Aljenfawi, K., Al-Anazi, S., Salman, F., Assaf, M. S., Mobarak, M., AlRoomi, E., et al. (2024) · Cureus · doi:10.7759/cureus.53606 · Cited by 3
“The current guidelines recommend carbapenemase gene testing to guide the ideal antimicrobial therapy choices [17].”
BackgroundInfluentialManaging Antimicrobial Resistance in the Emergency Department
Yeary, J. C., Hacker, L., & Liang, S. Y. (2024) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2024.02.005 · Cited by 3
Mokrani, D., & Luyt, C. E. (2024) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001039 · Cited by 3
Khunkit, P., Siripaitoon, P., Lertsrisatit, Y., Watthanapaisal, D., Kositpantawong, N., Kanchanasuwan, S., Cheh-oh, N., Chittrakarn, S., Jaroenmark, T., Poonchuay, N., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13080729 · Cited by 3
Clinical Challenge: Standard Versus Extended Meropenem Infusion in Children
Kişi, A. E., Aykaç, K., & Özsürekçi, Y. (2024) · Turkish Archives of Pediatrics · doi:10.5152/turkarchpediatr.2024.23245 · Cited by 3
Bansal, N., Sukhwani, K., & Ganta, V. (2025) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2025.2453581 · Cited by 3
“Use of cef-avi based therapy is already proven to superior to colistin based therapy in various observational studies [5,13].”
Cui, Y., Feng, X., Pan, L., Lin, Q., Wang, J., Zhen, S., Fan, Y., Chen, X., Zheng, Y., Mi, Y., et al. (2025) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-025-00801-y · Cited by 3
“According to the IDSA [22], carbapenem monotherapy should be used as the first-line treatment for ESBL-E BSI, based on results from MERINO trial [13], which compared the efficacy of BLBLI with carbapenems.”
Faizal, B., P, S. K. K., Radhakrishnan, S. R., Manoj, M. P., Shaira, K. P., Sarafudeen, P. K., T, I. A., Dominic, M., George, R. R., George, B. R., et al. (2025) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-025-09613-4 · Cited by 3
Hayakawa, K., Bình, N. G., Co, D. X., Thạch, P. T., Pham, T. T. P., Chau, N. Q., Huong, M. L., Thành, Đ. V., Phuong, D. M., Miyoshi‐Akiyama, T., et al. (2023) · Infection Prevention in Practice · doi:10.1016/j.infpip.2023.100318 · Cited by 3
Difficult to Treat Gram-Negative Bacteria—The Indian Scenario
Bannore, N., Kapadia, F. N., & Hegde, A. V. (2024) · Current Infectious Disease Reports · doi:10.1007/s11908-024-00834-y · Cited by 3
Kimura, Y., Hatayama, N., Sato, Y., Nishida, S., & Yoshino, Y. (2024) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2023.364 · Cited by 3
Balandín, B., Pintado, V., Sánchez-Belmonte, M. J. P.-P., Martínez‐Sagasti, F., Sancho-González, M., Soriano, C., Gesso, C. M.-D., Chicot, M., de Luna, R. R., Asensio-Martín, M. J., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107121 · Cited by 3
Mayhew, J. A., Christenson, J. C., & Alali, M. (2024) · Translational Pediatrics · doi:10.21037/tp-23-492 · Cited by 3
“The clinical significance of this has been questioned, however, as overexpression of AmpC occurs in 5% of isolates (20) and varies by antibiotic (19).”
Microbiology and Treatment of Diabetic Foot Infection
LaSalvia, M. T., & Karchmer, A. W. (2024) · Contemporary diabetes · doi:10.1007/978-3-031-55715-6_20 · Cited by 3
Lo, C. K.-F., Ritchie, G., Bilawka, J., Gowland, L., Chorlton, S. D., Jang, W., Matic, N., Romney, M. G., Stefanovic, A., & Lowe, C. F. (2024) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001881 · Cited by 3
“Novel antimicrobials have been developed in response to combat carbapenem-resistant pathogens such as ceftazidime-avibactam, though some novel agents do not cover all CPE, specifically those harbouring metallo-β -lactamases [3].”
Khreis, D., Dalle, S., Akel, S. R., & Hanna‐Wakim, R. (2024) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004573 · Cited by 3
“20 To note that C. koseri isolates typically do not carry the genes encoding AmpC β -lactamases that are inducible.”
Carbapenemase Mechanism Testing to Support Treatment, Infection Control, and Public Health
Blosser, S. J., Bhatnagar, A. S., Bollinger, S., & Giffen, S. R. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2024.10.006 · Cited by 3
TO MARKET, TO MARKET—2023: SMALL MOLECULES
Araujo, E., Bartels, B., Bell, I. M., Castanedo, G. M., Zeng, M., Dhar, T. G. M., Holmberg‐Douglas, N., Welin, E. R., Koester, D. C., León, B., et al. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch19 · Cited by 3
Dumont, R., Lengliné, É., Delorme, C., Bru, J. P., Ansart, S., Aslangul, E., Kelley, S., Cochat, P., Chevret, S., & Diatta, T. (2024) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462324000552 · Cited by 3
Karadoğan, E., Sertçelik, A., Dizman, G. T., Uzar, H., Hazırolan, G., Cakir, B., & Metan, G. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae476 · Cited by 4
Dekhnich, A. V., Kuzmenkov, A. Y., Попов, Д. А., Shlyk, I. V., & Edelstein, M. V. (2023) · Messenger of Anesthesiology and Resuscitation · doi:10.24884/2078-5658-2022-20-2-96-107 · Cited by 3
Ng, T. H., Zhao, J. J., Gumbleton, R., Olson, S., Smith, S. R., & Scipione, M. R. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231201953 · Cited by 4
Treatment of Acinetobacter baumannii
Warrier, A. R., & Radha, S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003593 · Cited by 3
Böhringer, N., Wuisan, Z. G., Marner, M., Kresna, I. D. M., Mettal, U., Schmitt, S., Reiter, S., Liu, Y., Brinkrolf, K., Rupp, O., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.30.596569 · Cited by 3
“(48) The unformulated compounds are hydrophilic and highly soluble in water.”
BackgroundRodjun, V., Montakantikul, P., Houngsaitong, J., Jitaree, K., & Nosoongnoen, W. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1275909 · Cited by 2
Bouwman, K., & George, M. (2024) · Antibiotics · doi:10.3390/antibiotics13060552 · Cited by 2
“Oral options for Pseudomonas aeruginosa are limited to fluoroquinolones, which have increasing resistance, a large number of side effects such as QT prolongation and tendon rupture, and multiple drug interactions [2,9].”
BackgroundInfluentialYu, J., Zhang, B., Yang, Y., Dou, W., Li, Y., Yang, A., Ruan, X., Zuo, W., & Zhang, B. (2024) · Infection · doi:10.1007/s15010-024-02307-9 · Cited by 2
Shallal, A. B., Veve, M. P., Kenney, R. M., Alangaden, G. J., & Suleyman, G. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.11.017 · Cited by 2
Yang, S., & Wei, C. (2024) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2024.102150 · Cited by 2
“In the 2023 Infectious Diseases Society of America (IDSA) guidelines for anti infective treatment, experts recommend using at least two active drugs in combination to treat carbapenem-resistant Acinetobacter baumannii (CRAB) infections before clinical efficacy improves [9].”
Al-Aamri, B., Al‐Breiki, A., Hazra, D., Al-Aamri, T., & Al-Shehi, M. (2025) · Current Medical Issues · doi:10.4103/cmi.cmi_120_24 · Cited by 2
Matuoka, J. Y., Pachito, D. V., Piastrelli, F. T., Fehlberg, L. C. C., & de Oliveira, H. A. (2025) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2025.104545 · Cited by 2
“3,4,7 To raise awareness among the medical community and promote an evidence-based use of antimicrobials among patients with VAP, a cost-effectiveness analysis was conducted to compare CAZ-AVI with polymyxin B for the treatment of Carbapenem-Resistant Enterobacterales (CRE) or Carbapenem-Resistant…”
Bittencourt, A. A., Faustino, V. L., Batista, P. D. M., Leonel, L. P., de Paula, M. D. N., & Polis, T. J. B. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02543-24 · Cited by 2
Garg, I., Chauhan, N. K., Vardhan, H., Sankanagoudar, S., Dutt, N., Durgeshwar, G., Iyer, H. K., Kothari, N., Gadepalli, R., & Kumar, D. (2025) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2025.3225 · Cited by 2
Tian, D., Zhao, M., Liu, L., Lu, S., & Dong, H. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1548300 · Cited by 3
Ibarra-Rodríguez, Á., González-Gómez, J. P., Castillo-Olea, M. Á., Gómez‐Gil, B., Campo, N. C., & Cháidez, C. (2025) · Current Microbiology · doi:10.1007/s00284-025-04371-2 · Cited by 2
Montrucchio, G. G., Corcione, S., Rodigari, L., Barganou, D., Risso, C., Traversi, R., Sales, G., Ellena, M., Costamagna, A., Shbaklo, N., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165688 · Cited by 2
“According to the literature, the combination of ceftazidime–avibactam (CZA) and aztreonam (ATM) has been associated with a reduced risk of mortality compared to colistin-containing regimens [32] and is currently recommended as a first-line option against MBL [29–32].”
Cincotta, S. E., Ostrowsky, B. E., Howard-Anderson, J. R., Beekmann, S. E., Polgreen, P. M., & Walters, M. S. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf371 · Cited by 2
Blanco, A. C., Sáez, A. B. G., Cristobal, C. P., Cerón, I. F., Valcayo, A. M., Cintas, M. I. Z., & Sacristán, M. S. (2025) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2025.107311 · Cited by 2
Yeoh, D. K., Boast, A., Wen, S. C.-H., Williams, P. C. M., VOSS, L. M., Ritchie, B. K., Mostaghim, M., Lutui, F., Lei, A., Lai, T., et al. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101735 · Cited by 3
“Consensus treatment guidelines for MDR Gram-negative infections predominantly in adult patients, have been recently published, 25,26 with a number of previous paediatric reviews providing recommendations summarised in Table 1.”
InfluentialAhmad, N., Joji, R. M., Saeed, N. K., & Shahid, M. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.103087 · Cited by 2
Yang, X., He, N.-H., Haque, A., Mai, Y., Wang, J., Xiao, S.-N., & Zhuo, C. (2026) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-025-00847-y · Cited by 2
Yıldız, S. S., Arıcasoy, Ö. N., Bakkaloğlu, Z., Ünaldı, Ö., Hekimoğlu, C. H., Güreser, A. S., Mumcuoğlu, İ., & Dal, T. (2026) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2026.02859 · Cited by 3
Alotaibi, B. S., Syed, F., Almufarriji, F. M., & Tantry, B. A. (2026) · Frontiers in Antibiotics · doi:10.3389/frabi.2025.1700157 · Cited by 2
Marecik, T., Gąsiorowski, K., Bargiel, J., Wyszyńska–Pawelec, G., & Gontarz, M. (2026) · Oral · doi:10.3390/oral6010017 · Cited by 2
“Alternative regimens for patients intol-erant to β -lactams include fluoroquinolones, particularly ciprofloxacin (400 mg IV every 8 h, followed by 500–750 mg orally twice daily) [17,18].”
Li, D., Li, K., Dong, H., Gong, D., Shen, C., Pei, Y., Ren, D., Yang, S., Lu, Z., Wu, N., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12960-0 · Cited by 2
“The Infectious Diseases Society of America and European Society of Clinical Microbiology and Infectious Diseases guidelines recommend ceftazidime-avibactam as a first-line treatment option for CRKP infections [18, 19].”
Li, J., Liu, Z. H., Wang, H., Xia, Y., Hu, Y., Wang, H., Xia, F., & Zou, M. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-52233-z · Cited by 2
Managing sepsis in the era of precision medicine: a narrative review
Yong, H. J., Kim, S., & Kim, D. (2026) · Acute and Critical Care · doi:10.4266/acc.000884 · Cited by 2
Hamed, K. A., Salama, A., Moeck, G., & Wagenlehner, F. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2700381 · Cited by 2
“Similar constraints apply in patients with significant renal impairment, in whom reduced urinary excretion may limit the efficacy of nitrofurantoin and fosfomycin, and pharmacokinetic adjustment is required for aminoglycosides and β-lactams [33].”
InfluentialKapoor, A., Gupta, A., Sansar, B., Mishra, B. K., Singh, M., Sarode, R. J., Bajpai, V., Singh, A., Bharti, S., Mishra, A., et al. (2026) · BioMed Research International · doi:10.1155/bmri/6806493 · Cited by 2
“If lab tests confirm the absence of carbapenemase, high-dose carbapenems (e.g., meropenem in extended infusion) may still be useful [48, 49].”
InfluentialSoanker, R., Vemu, L., Vimala, S., Padmaja, K., Thumma, V. M., & Chavala, G. (2024) · Cureus · doi:10.7759/cureus.52023 · Cited by 2
Therapeutic Drug monitoring of colistin in critically ill patients: A narrative review
Ghoneim, R. H. (2023) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_33_23 · Cited by 2
Hayano, S., Hidaka, T., Tadakuma, R., & Kashima, M. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae026 · Cited by 2
“However, piperacillin-tazobactam is not recommended for the treatment of complicated UTI against ESBL-producing bacteria [23].”
BackgroundBajpai, V., Tiwari, S., Mishra, A., Sure, R. K., Sarode, R. J., Bharti, S., Pandey, H., & Kapoor, A. (2024) · Microbial Drug Resistance · doi:10.1089/mdr.2022.0313 · Cited by 2
Caffrey, A. R., Appaneal, H. J., Lopes, V., Riccobene, T. A., & LaPlante, K. L. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae038 · Cited by 2
The changing landscape of infections in the lung transplant recipient
Lum, J., & Koval, C. E. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001060 · Cited by 2
Govindaraju, G., Rajaiah, B., Ramakrishnan, S., Thangaraju, D., Chandrasekar, P., & Abiramalatha, T. (2024) · The Indian Journal of Pediatrics · doi:10.1007/s12098-024-05116-y · Cited by 2
Defeating the Silent Enemy: Antimicrobial Resistance Looming as the Next Global Pandemic
TIWASKAR, M. H., Vora, A., Saraf, A., Bhadade, R. R., Choudhari, S., Pawar, D., & Sharma, A. D. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0487 · Cited by 2
Santosaningsih, D., Yusuf, E. N., & Fatoni, A. Z. (2024) · majalah kesehatan · doi:10.21776/majalahkesehatan.2024.011.01.1 · Cited by 3
Almohareb, S. N., Aldairem, A. O., Alsuhebany, N., Alshaya, O. A., Aljatli, D., Alnemer, H., Almutairi, K. K., Aljammaz, N. A., & Alowais, S. A. (2024) · SAGE Open Medicine · doi:10.1177/20503121241259993 · Cited by 2
“5,6 According to the Infectious Diseases Society of America (IDSA) guidelines, the selection of empiric regimens should be guided by institutional susceptibility patterns and encourage urine cultures to be obtained for patients at risk of UTIs with multidrug-resistant (MDR) pathogens.”
BackgroundIjaz, S., Ansari, F., Nawaz, M., Ejaz, H., Anjum, A. A., Saeed, A., Ali, T., Rehman, O. U., Fatima, E., & Ijaz, T. (2024) · Medicina · doi:10.3390/medicina60071086 · Cited by 2
“However, it is recommended to avoid using colistin as monotherapy in cases of A. baumannii to prevent antimicrobial resistance development [6–8].”
BackgroundJiang, L., Yin, D., Song, P., Tang, C., Liu, X., & Hu, F. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04889-6 · Cited by 2
Yang, X., Wang, T., Zhang, B., Zhang, W., Wu, G., Xu, D., Liu, D., & He, Y. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107273 · Cited by 2
Kulaç, Ö., Başkan, C., Koşar, N., BALCI, P., Havuz, S. G., & Sırıken, B. (2024) · Biologia · doi:10.1007/s11756-024-01763-w · Cited by 2
“The problem of antimicrobial resistance (AMR), which has been caused by using antibiotics for many years to treat infectious diseases, has become a major crisis around the world (Navon et al. 2017; Tamma et al. 2023).”
The evolution of knowledge for treating Gram-negative bacterial infections
Burillo, A., & Bouza, E. (2024) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001055 · Cited by 2
Sablone, S., Cardinale, A. N., Gorini, E., Diella, L., Belati, A., Bussini, L., Cento, V., Bartoletti, M., Introna, F., & Bavaro, D. F. (2024) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2024.102762 · Cited by 2
Song, S., Liu, J., Su, W., Yu, H., Feng, B., Wu, Y., Guo, F., & Yu, Z. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s473080 · Cited by 2
Çaydaşı, Ö., Arslan, E., Çetin, A. Ş., Karadağ, F. Y., Dede, A. T., Adıyeke, E., Gündoğuş, N., & Öztürk-Engin, D. (2024) · Jundishapur Journal of Microbiology · doi:10.5812/jjm-150331 · Cited by 3
Sreenithya, K. H., & Sugumar, S. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00270-9 · Cited by 2
“It can also hydrolyze some no beta-lactam compounds such as aztreonam and nitrocefin (Tamma et al. 2023).”
Coggins, S. A., Wade, K. C., Watt, K., Downes, K. J., & Puopolo, K. M. (2024) · Pediatric Research · doi:10.1038/s41390-024-03698-z · Cited by 2
Antibacterial Therapy Options for Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
Goncharova, A. R., Валерьевич, Г. В., Goncharov, N. E., Kalinogorskaya, O. S., & Сергеевич, Г. Н. (2024) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2024-69-7-8-53-66 · Cited by 2
Yanagihara, K., Kurihara, D., & Kimata, M. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.11.019 · Cited by 2
Lane, L. C., Walker, J. K., & Hill, D. M. (2025) · Microorganisms · doi:10.3390/microorganisms13020330 · Cited by 2
Shiqi, C., Chuhui, W., Yijing, Z., Qiu, Y., Jiaojiao, C., Chen, K., Qindong, S., Xiaoyan, Z., & Yalin, D. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05063-2 · Cited by 2
Thabit, A. K., Sulaiman, K. A. A., Alfaraj, L. A., Radwan, S. A., Almadfaa, L. O., Mokhtar, R. H., Alowais, S. A., Saleh, K. B., Eljaaly, K., Alzahrani, A. A., et al. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251315950 · Cited by 2
“16 In a single-arm retrospective study, nitro-furantoin was shown to be effective against ESBL-producing E. coli and can be used as an alternative for cystitis.”
InfluentialFouad, A., Nicolau, S. E., Tamma, P. D., Simner, P. J., Nicolau, D. P., & Gill, C. M. (2025) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2025.2471822 · Cited by 2
Self-citationCommon Infections in the Intensive Care Unit
Mahmoud, A. A., Halawi, H., Sabawi, M. M., & Adelman, M. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-77335-8_29 · Cited by 2
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.